Advertisement
UK markets closed
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     
  • CRUDE OIL

    82.88
    +0.07 (+0.08%)
     
  • GOLD FUTURES

    2,330.00
    -8.40 (-0.36%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • Bitcoin GBP

    51,507.37
    -1,820.24 (-3.41%)
     
  • CMC Crypto 200

    1,387.43
    -36.67 (-2.57%)
     
  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     
  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     

Novo Nordisk Focuses on Expanding Semaglutide’s Label

Novo Nordisk Focuses on Expanding Semaglutide’s Label

Based on readouts from this study, the company plans to evaluate the efficacy and safety of once-a-week semaglutide therapy in NASH indications in its Phase 3 trial. According to a Diabetes Care report, ~80% of NASH patients suffer from obesity.